Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare mitochondrial disease: oral drug trial launches

NCT ID NCT06644534

Recruiting now Disease control Sponsor: Thiogenesis Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 24 times

Summary

This study tests an oral medication called TTI-0102 in 12 people with MELAS, a rare genetic disorder that causes muscle weakness, strokes, and fatigue. Participants receive either the drug or a placebo for 6 months to see if it improves walking distance, tiredness, and quality of life. The goal is to find a safe treatment that helps control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL ENCEPHALOMYOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Angers University Hospital Center (CHU Angers)

    RECRUITING

    Angers, 49100, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Radboud University Medical Center

    RECRUITING

    Nijmegen, 6500 HB, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

MELAS SYNDROME MITOCHONDRIAL ENCEPHALOMYOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS)